Transcriptomic classification of prolactinomas and somatotropinomas identifies subtypes with variable resistance to treatment
Authors' conclusion
Prolactinomas and somatotropinomas were classified into distinct transcriptomic groups. Resistance to medical therapies was linked to distinct tumor subtypes, suggesting distinct mechanisms of resistance.
Study context
- Population
- Prolactinomas and somatotropinomas treated with dopamine agonists or somatostatin analogs46 prolactinomas · 58 somatotropinomas
- Outcome
- Distinct molecular subtypes of prolactinomas and somatotropinomas and their association with response to treatment
Methodological detailstranscriptomic, unsupervised classification
- Transcriptomic
- Unsupervised classification
Main finding
As reported in the abstract
- Four prolactinoma subtypes with variable sensitivity to dopamine agonists
- P < 10-4
- Remaining somatotropinomas in 5 subtypes with variable sensitivity to SSA
- P < 10-4
Further findings
SSTR2 expression and response to SSA
- Associated with response in sparsely granulated somatotropinomas
- P = 0.022
- Not associated in other somatotropinomas
- P = 0.923
Original publication
Transcriptomic classification of prolactinomas and somatotropinomas identifies subtypes with variable resistance to treatment. Eur J Endocrinol. Published 27 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →